UCSF adult and pediatric clinical trials

UCSF Brain Tumor Center Clinical Trials

Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors. 

Identify Relevant Clinical Trials
Clinical Trial Phase
Intervention Model
Treatment Modality
Which of the following treatments has the patient already received?*
Genetic Features*
  • Recruiting Recruiting
  • Pediatrics Pediatrics
  • On Hold On Hold
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
DCC-2618 is an orally administered drug designed to inhibit the activity of proteins called KIT and PDGFRα. KIT and PDGFRα are proteins that are mutated or abnormally active in variety of cancer cell types; when mutated, these proteins can increase tumor cell proliferation and resistance to chemotherapy.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Ependymoma
Medulloblastoma
This phase I clinical trial will evaluate the safety and tolerability of a single tumor injection of Ad-RTS-hIL-12 given with veledimex, for pediatric patients with brain tumors.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Summary

The purpose of this Phase I/II clinical trial is to evaluate the dosage, safety and efficacy of pembrolizumab in treating pediatric participants with any of the following types of cancer:

Conditions
Glioma
Astrocytoma
Diffuse Midline Glioma
Brainstem Glioma
This Phase I clinical trial will assess the safety and preliminary efficacy of delivering nal-IRI (a specialized formulation of irinotecan, a chemotherapy drug) directly into the brain through convection enhanced delivery, in treating children with newly diagnosed DIPG.
Conditions
Glioma
Oligodendroglioma
Astrocytoma
Diffuse astrocytoma (grade II)
The purpose of this study is to investigate the effect of a drug called everolimus (RAD001, or Afinitor) alone or in combination with temozolomide (a chemotherapy drug) in treating patients with newly diagnosed low-grade glioma. 

Stay Informed